Thelansis

  Recurrence of high-grade gliomas, including glioblastoma multiforme (grade IV) and anaplastic astrocytoma (grade III), poses an unavoidable challenge. Despite aggressive surgical resection of the primary tumor and subsequent adjuvant re-chemoradiation, patients face a dismal prognosis, with a median survival of only 11 months. Typically, recurrence manifests during MRI examinations, revealing tumor enlargement accompanied by increased edema and a noticeable mass effect. Currently, there is no established standard of treatment for managing recurrent high-grade gliomas. Options such as re-resection, re-irradiation, and chemotherapy are available, but their long-term efficacy remains unproven. Glioblastoma recurrence typically occurs approximately 32–36 weeks after initial multimodal treatment, often due to ongoing neoplastic growth within 2–3 cm of the original lesion. Thelansis’s “Recurrent High-Grade Glioma Market Outlook, Epidemiology, Competitive Landscape, and Market Fore...